Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronicles in drug discovery.

Shelley L Davies1, Maria Angels Moral, Jordi Bozzo

  • 1Prous Science, Barcelona, Spain. journals@prous.com

Drug News & Perspectives
|April 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2021
Same author

A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2020
Same author

Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role.

Expert review of anti-infective therapy·2017
Same author

Ticagrelor.

Drugs of today (Barcelona, Spain : 1998)·2010
Same author

Dexlansoprazole for the treatment of esophagitis and GERD.

Drugs of today (Barcelona, Spain : 1998)·2010
Same author

Spotlight on autoimmune lymphoproliferative syndrome.

Drug news & perspectives·2007

This report covers new drug discovery advances, including agents depleting immunosuppressive T cells for cancer therapy, novel antivirals for respiratory syncytial virus, gene therapies for Huntington's disease, and anti-inflammatory compounds for pain relief.

Area of Science:

  • Oncology
  • Virology
  • Neurology
  • Pharmacology

Background:

  • Tumor cells produce immunosuppressive regulatory T cells, hindering anti-tumor immunity and chemotherapy effectiveness.
  • Current antiviral treatments for respiratory syncytial virus (RSV) are limited by side effects and cost.
  • Huntington's disease therapies are evolving, with gene-based and cell-based approaches showing promise.
  • The somatostatin receptor subtype 4 (sst4) is a potential target for novel anti-inflammatory and analgesic drugs.

Purpose of the Study:

  • To review recent advancements in drug discovery across multiple therapeutic areas.
  • To highlight novel therapeutic strategies targeting immunosuppressive cells, viral infections, neurodegenerative diseases, and pain management.

Main Methods:

Related Experiment Videos

  • Review of current clinical developments and research findings.
  • Focus on agents targeting regulatory T cells, respiratory syncytial virus, Huntington's disease, and the sst4 receptor.

Main Results:

  • Agents targeting regulatory T cells show potential in cancer therapy.
  • New monoclonal antibodies, siRNAs, vaccines, and small molecule inhibitors are in development for RSV.
  • Gene therapies and cellular transplantation are emerging as treatments for Huntington's disease.
  • Compounds targeting sst4 demonstrate anti-inflammatory and antinociceptive properties.

Conclusions:

  • Significant progress is being made in developing novel therapeutics for cancer, viral infections, Huntington's disease, and pain.
  • Targeting specific cellular mechanisms and pathways offers promising avenues for future drug discovery.